Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Plasma cell 2Lymphoid 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Malignant Solid Neoplasm 1

Interventions

pembrolizumab 7Specimen Handling 7tislelizumab 6Cisplatin 6Carboplatin 6atezolizumab 5Pemetrexed 5Bevacizumab 5Platinum 4Interviews as Topic 4Injections 4Educational Status 4Cyclophosphamide 4Biopsy 4fludarabine 3Nivolumab 3Methods 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Early Intervention, Educational 31,2-diaminocyclohexaneplatinum II citrate 3sintilimab 2sacituzumab govitecan 2X-Rays 2Trastuzumab 2Standard of Care 2Radiotherapy 2Radiation 2Practice Guidelines as Topic 2Palliative Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
copanlisib × Other solid neoplasm × 30 days × Clear all
NCT06360588 2026-05-28

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
22 enrolled 9 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡